NYSE:NAVB Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Navidea Biopharmaceuticals Stock (NYSE:NAVB) Get NAVB alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume7,146 shsMarket Capitalization$10 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Navidea Biopharmaceuticals, Inc. is a biotechnology company focused on precision immunodiagnostic and radiopharmaceutical products. Its research has centered on the Manocept platform, which is designed to target CD206 receptors found on certain macrophages and other immune-system cells. The company’s principal product is Lymphoseek (technetium Tc 99m tilmanocept injection), a diagnostic imaging agent used to help identify and map lymph nodes during the evaluation and surgical treatment of certain cancers. Lymphoseek has received U.S. regulatory approval for lymphatic mapping in patients with breast cancer and melanoma, as well as for patients with head and neck cancer. Navidea has historically pursued additional applications for the Manocept platform in oncology, inflammatory diseases and other conditions involving macrophage activity. The company has worked with commercial and development partners to support the distribution and further development of its products in the United States and international markets. Information about its current operations and leadership may be limited because the company’s business and corporate status have changed over time.AI Generated. May Contain Errors. Read More Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAVB Stock News HeadlinesNavidea Biopharmaceuticals, Inc. Files for BankruptcyOctober 8, 2025 | businesswire.comNavidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock SplitMay 21, 2025 | businesswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax AssetsMarch 31, 2025 | businesswire.comNavidea Biopharmaceuticals Inc. (NAVB) Latest Pre Market TradesDecember 23, 2024 | nasdaq.comNavidea Biopharmaceutical (OTC:NAVB) Stock Quotes, Forecast and News SummaryOctober 28, 2024 | benzinga.comNavidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024July 3, 2024 | businesswire.comNavidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024June 20, 2024 | businesswire.comSee More Headlines NAVB Stock Analysis - Frequently Asked Questions How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The firm earned $0.10 million during the quarter, compared to analyst estimates of $0.60 million. What other stocks do shareholders of Navidea Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Navidea Biopharmaceuticals investors own include Novavax (NVAX), OPKO Health (OPK), Tesla (TSLA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Agenus (AGEN). Company Calendar Last Earnings11/10/2021Today10/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NAVB CIK810509 Webwww.navidea.com Phone614-793-7500Fax614-793-7522Employees10Year Founded1983Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$8.13 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares100,080,000Free Float56,367,000Market Cap$10 thousand OptionableNo Data Beta1.76 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NYSE:NAVB) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
